DF
TNDM icon

Donoghue Forlines’s Tandem Diabetes Care TNDM Stock Holding History

Donoghue Forlines’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,587
Closed -$331K – 286
2022
Q2 		$331K Sell
5,587
-539
-9% -$44.2K 0.09% 252
2022
Q1 		$712K Buy
6,126
+1,941
+46% +$227K 0.15% 222
2021
Q4 		$630K Buy
+4,185
New +$565K 0.11% 207

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Donoghue Forlines's TNDM Position: Q3 2022 in Review

Donoghue Forlines sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 5,587 shares — an estimated $331K sold.

Donoghue Forlines first reported a position in TNDM in Q4 2021 and held it in 3 quarters. The position peaked at $712K in Q1 2022. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

  • Donoghue Forlines reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
  • Donoghue Forlines sold 5,587 Tandem Diabetes Care shares in Q3 2022, an estimated $331K.
  • Donoghue Forlines first reported a position in Tandem Diabetes Care in Q4 2021 and held it in 3 quarters.
  • Donoghue Forlines's Tandem Diabetes Care position peaked at $712K in Q1 2022.
  • 299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on Donoghue Forlines's 13F filing for Q3 2022, filed 7 Nov 2022.